Compare Amphastar Pharmaceuticals Inc (AMPH) vs Flux Power Holdings Inc (FLUX) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

FLUX trades at $0.7765, up 0.36% today, but technical indicators show a bearish trend with moving averages signaling sell. The company reported a net loss of $6.67 million in 2025, with revenue declining to $51 million in 2026, though it maintains a low P/S ratio of 0.29. Recent news highlights the launch of SkyEMS 3.0 AI software, aiming to boost operational efficiency for fleet customers.

Despite unanimous analyst buy ratings, FLUX faces significant profitability challenges with negative ROE and net margins. Investment appeal hinges on revenue stabilization and cost management, but high execution risk and cash flow volatility warrant caution for stock investors.